<?xml version='1.0' encoding='utf-8'?>
<document id="30217228"><sentence text="Research on the mechanism of drug-drug interaction between salvianolate injection and aspirin based on the metabolic enzyme and PK-PD model: study protocol for a PK-PD trial."><entity charOffset="59-71" id="DDI-PubMed.30217228.s1.e0" text="salvianolate" /><entity charOffset="86-93" id="DDI-PubMed.30217228.s1.e1" text="aspirin" /><pair ddi="false" e1="DDI-PubMed.30217228.s1.e0" e2="DDI-PubMed.30217228.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30217228.s1.e0" e2="DDI-PubMed.30217228.s1.e1" /></sentence><sentence text="Coronary heart disease (CHD) is a common cardiovascular disease accounting for 10-20% mortality by heart disease worldwide" /><sentence text=" The gold standard treatment to manage CHD is aspirin, which may prevent myocardial infarction and sudden death; however, long-term use of aspirin may increase its side effects"><entity charOffset="5-9" id="DDI-PubMed.30217228.s3.e0" text="gold" /><entity charOffset="39-42" id="DDI-PubMed.30217228.s3.e1" text="CHD" /><entity charOffset="46-53" id="DDI-PubMed.30217228.s3.e2" text="aspirin" /><entity charOffset="139-146" id="DDI-PubMed.30217228.s3.e3" text="aspirin" /><pair ddi="false" e1="DDI-PubMed.30217228.s3.e0" e2="DDI-PubMed.30217228.s3.e0" /><pair ddi="false" e1="DDI-PubMed.30217228.s3.e0" e2="DDI-PubMed.30217228.s3.e1" /><pair ddi="false" e1="DDI-PubMed.30217228.s3.e0" e2="DDI-PubMed.30217228.s3.e2" /><pair ddi="false" e1="DDI-PubMed.30217228.s3.e0" e2="DDI-PubMed.30217228.s3.e3" /><pair ddi="false" e1="DDI-PubMed.30217228.s3.e1" e2="DDI-PubMed.30217228.s3.e1" /><pair ddi="false" e1="DDI-PubMed.30217228.s3.e1" e2="DDI-PubMed.30217228.s3.e2" /><pair ddi="false" e1="DDI-PubMed.30217228.s3.e1" e2="DDI-PubMed.30217228.s3.e3" /><pair ddi="false" e1="DDI-PubMed.30217228.s3.e2" e2="DDI-PubMed.30217228.s3.e2" /><pair ddi="false" e1="DDI-PubMed.30217228.s3.e2" e2="DDI-PubMed.30217228.s3.e3" /></sentence><sentence text=" Currently, more and more clinicians are exploring different approaches to use the right combination of medicine to enhance the efficacy and reduce side effects" /><sentence text=" Salvianolate can significantly inhibit the aggregation and activation of platelets in patients with CHD; however, its optimum combination with western medicine is not established or supported by clinical trial results"><entity charOffset="1-13" id="DDI-PubMed.30217228.s5.e0" text="Salvianolate" /><entity charOffset="101-104" id="DDI-PubMed.30217228.s5.e1" text="CHD" /><pair ddi="false" e1="DDI-PubMed.30217228.s5.e0" e2="DDI-PubMed.30217228.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30217228.s5.e0" e2="DDI-PubMed.30217228.s5.e1" /></sentence><sentence text="" /><sentence text="This trial is a prospectively planned, open-labeled, parallel-grouped, single-centered clinical trial with aggregated pharmacodynamics-pharmacokinetics (PK-PD) data" /><sentence text=" All treatment courses will last for 10 days and blood sample will be acquired before administration on days 8, 9, and 10, and after administration at 5 min, 15 min, 30 min, 45 min, 1 h, 2 h, 4 h, 8 h, 12 h, and 24 h on day 10" /><sentence text=" This trial uses PK-PD modeling to provide a description of the concentration-effect relationship and an estimate of pharmacological potency of the medicine" /><sentence text=" The primary outcome will be changes in aspirin esterase and catechol-o-methyltransferase (COMT) activity at different blood concentrations to determine the PK-PD characteristics of the combination of salvianolate and aspirin, followed by analysis of the correlation between exposure level and pharmacodynamic index of the medicines"><entity charOffset="40-47" id="DDI-PubMed.30217228.s10.e0" text="aspirin" /><entity charOffset="201-213" id="DDI-PubMed.30217228.s10.e1" text="salvianolate" /><entity charOffset="218-225" id="DDI-PubMed.30217228.s10.e2" text="aspirin" /><pair ddi="false" e1="DDI-PubMed.30217228.s10.e0" e2="DDI-PubMed.30217228.s10.e0" /><pair ddi="false" e1="DDI-PubMed.30217228.s10.e0" e2="DDI-PubMed.30217228.s10.e1" /><pair ddi="false" e1="DDI-PubMed.30217228.s10.e0" e2="DDI-PubMed.30217228.s10.e2" /><pair ddi="false" e1="DDI-PubMed.30217228.s10.e1" e2="DDI-PubMed.30217228.s10.e1" /><pair ddi="false" e1="DDI-PubMed.30217228.s10.e1" e2="DDI-PubMed.30217228.s10.e2" /></sentence><sentence text="" /><sentence text="This trial will aim to evaluate the relationship between changes in the pharmacokinetics and therapeutic effect index in the combined use of salvianolate and aspirin"><entity charOffset="141-153" id="DDI-PubMed.30217228.s12.e0" text="salvianolate" /><entity charOffset="158-165" id="DDI-PubMed.30217228.s12.e1" text="aspirin" /><pair ddi="false" e1="DDI-PubMed.30217228.s12.e0" e2="DDI-PubMed.30217228.s12.e0" /><pair ddi="false" e1="DDI-PubMed.30217228.s12.e0" e2="DDI-PubMed.30217228.s12.e1" /></sentence><sentence text=" It also discusses the possible mechanism of medicine combination in the treatment for CHD and provides an experimental basis for a clinically rational medicine combination"><entity charOffset="87-93" id="DDI-PubMed.30217228.s13.e0" text="CHD" /></sentence><sentence text="" /><sentence text="ClinicalTrials" /><sentence text="gov, NCT03306550 " /><sentence text=" Registered on 9 October 2017" /><sentence text=" ClinicalTrials" /><sentence text="gov https://register" /><sentence text="clinicaltrials" /><sentence text="gov/prs/app/action/SelectProtocol?sid=S0007D8H&amp;selectaction=Edit&amp;uid=U0003QY8&amp;ts=2&amp;cx=oiuc9g"><entity charOffset="19-92" id="DDI-PubMed.30217228.s21.e0" text="SelectProtocol?sid=S0007D8H&amp;selectaction=Edit&amp;uid=U0003QY8&amp;ts=2&amp;cx=oiuc9g" /></sentence><sentence text="" /></document>